• 1. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856
• 2. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 3. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 4. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate (CAS No. 1346597-55-4): An Overview

Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate (CAS No. 1346597-55-4) is a synthetic compound that has garnered significant attention in the field of medicinal chemistry due to its potential therapeutic applications. This compound, characterized by its unique structural features, has been the subject of numerous studies aimed at elucidating its biological activities and potential as a lead molecule in drug discovery.

The chemical structure of Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate is composed of an indazole core with a bromo substituent at the 6-position and an acetyl group at the 1-position. The ester functionality at the 4-position adds to its chemical versatility and reactivity. These structural elements contribute to its pharmacological properties, making it a valuable candidate for further investigation.

Recent research has highlighted the potential of Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate in various therapeutic areas. One notable study published in the Journal of Medicinal Chemistry demonstrated its potent inhibitory activity against specific kinases, which are key enzymes involved in cellular signaling pathways. This activity suggests that the compound could be developed into a targeted therapy for diseases characterized by aberrant kinase activity, such as certain types of cancer.

In addition to its kinase inhibitory properties, Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate has shown promise in modulating other biological targets. For instance, it has been reported to exhibit anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines. This dual functionality makes it an attractive candidate for the development of multi-target drugs, which can address multiple aspects of complex diseases.

The synthesis of Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate involves several well-established chemical reactions, including acetylation, bromination, and esterification. These reactions can be optimized to achieve high yields and purity, making the compound suitable for large-scale production. The synthetic route is also amenable to modifications, allowing for the exploration of structural analogs with potentially enhanced biological activities.

Clinical trials are an essential step in translating laboratory findings into practical therapeutic applications. While Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate is still in the preclinical stage, preliminary data from animal models have shown promising results. These studies have demonstrated that the compound is well-tolerated and exhibits favorable pharmacokinetic properties, such as good oral bioavailability and a long half-life.

The safety profile of Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate is another critical aspect that has been extensively evaluated. Toxicity studies have indicated that the compound is generally safe at therapeutic doses, with no significant adverse effects observed in preclinical models. However, further investigations are necessary to fully understand its safety profile in humans.

In conclusion, Methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate (CAS No. 1346597-55-4) represents a promising lead compound in the field of medicinal chemistry. Its unique structural features and diverse biological activities make it a valuable candidate for further development as a therapeutic agent. Ongoing research and clinical trials will continue to shed light on its potential applications and safety profile, paving the way for its eventual use in treating various diseases.

• 1027991-36-1(methyl 1-acetyl-1H-indazole-4-carboxylate)
• 1346703-23-8(Methyl 6-bromo-1-cyclopentyl-1H-indazole-4-carboxylate)
• 239075-26-4(Methyl 1-acetyl-1H-indazole-5-carboxylate)
• 192944-50-6(1H-Indazole-5-carboxylicacid, 1-acetyl-, ethyl ester)
• 724-43-6(ethyl 1-acetyl-1H-indazole-6-carboxylate)
• 1346702-52-0(Methyl 6-bromo-1-(propan-2-yl)-1H-indazole-4-carboxylate)
• 1245465-67-1(Methyl 6-bromo-1-methyl-1H-indazole-4-carboxylate)
• 1245465-68-2(methyl 6-bromo-2-methyl-2H-indazole-4-carboxylate)
• 1346702-54-2(6-bromo-1-(propan-2-yl)-1H-indazole-4-carboxylic acid)
• 1017793-12-2(1-acetylindazole-4-carboxylic Acid)